Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: A multicenter phase II DeCOG Trial with Long-Term Follow-Up

Clinical Cancer Research

Volumn 20, Issue 2, 2014, Pages 499-510

  Ugure, Selma ^a   Mentzel, Thomas ^b   Utikal, Jochen ^c,e   Helmbold, Peter ^d,f   Mohr, Peter ^g   Pföhler, Claudia ^h   Schiller, Meinhard ⁱ   Hauschild, Axel ^j   Hein, Rüdiger ^k   Kämpgen, Eckhardt ^l   Kellner, Ivonne ^m   Leverkus, Martin ^e   Becker, Jürgen C ^p   Ströbel, Philip ⁿ   Schadendorf, Dirk ^o  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Dermatopathologische Gemeinschaftspraxis   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g Elbe Klinikum Buxtehude   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j UNIVERSITY OF KIEL   (Germany)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^m HELIOS KLINIKUM ERFURT   (Germany)

ⁿ UNIVERSITY OF GÖTTINGEN   (Germany)

^o UNIVERSITY OF DUISBURG ESSEN   (Germany)

^p MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; INSULIN RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SUNITINIB;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; DEPRESSION; DERMATOFIBROSARCOMA PROTUBERANS; DISTANT METASTASIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NUCLEOTIDE SEQUENCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; BIOLOGICAL MARKERS; DERMATOFIBROSARCOMA; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ONCOGENE PROTEINS, FUSION; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84892742296     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1411     Document Type: Article

References (28)

1. Weiss SW, Goldblum JR. Fibrohistiocytic tumors of intermediate malignancy. In: Weiss SW, Goldblum JR, editors. St. Louis, MO: Mosby; 2001. p.853-87.
2. MendenhallWM,Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. Cancer 2004;101:2503-8.
3. Becker JC, Liegl-Atzwanger B, Ugurel S. Malignant fibrous, fibrohistiocytic, and histiocytic tumors of the dermis. In: Goldsmith LA, Katz SI, Gilchrest BA, Palle AS, editors. Fitzpatrick's dermatology in general medicine. 8 ed. New York, NY: Mcgraw-Hill; 2012. p.1445-56.
4. Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004;30:341-5.
5. Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, et al. Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000;88:2711-20.
6. Fiore M, Miceli R, Mussi C, Lo VS, Mariani L, Lozza L, et al. Dermatofibrosarcoma protuberans treated at a single institution: A surgical disease with a high cure rate. J Clin Oncol 2005;23: 7669-75.
7. Voth H, Landsberg J, Hinz T, Wenzel J, Bieber T, Reinhard G, et al. Management of dermatofibrosarcoma protuberans with fibrosarcomatous transformation: an evidence-based review of the literature. J Eur Acad Dermatol Venereol 2011;25:1385-91.
8. Farma JM, Ammori JB, Zager JS, Marzban SS, Bui MM, Bichakjian CK, et al. Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol 2010;17:2112-8.
9. Simon MP, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre JM, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997;15:95-8.
10. Shimizu A, O'Brien KP, SjoblomT, Pietras K, Buchdunger E, Collins VP, et al. The dermatofibrosarcoma protuberans-associated collagentype I alpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999;59:3719-23.
11. Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 2001;92:254-360.
12. Sjuoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61: 5778-83.
13. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, et al. Molecular targeting of platelet-derived growth factorBby imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-91.
14. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002; 100:623-6.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
16. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-80.
17. Kutzner H, Mentzel T, Palmedo G, Hantschke M,Rütten A, Paredes BE, et al. Plaque-like CD34-positive dermal fibroma ("medallion-like dermal dendrocyte hamartoma"): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans. Am J Surg Pathol 2010;34:190-201.
18. Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007;177:489-500.
19. Malhotra B, Schuetze SM. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: A review of clinical trial results. Curr Opin Oncol 2012;24:419-24.
20. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec- Rychter M, Corless CL, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-73.
21. Rutkowski P, Van GM, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010;28:1772-9.
22. Kerob D, Porcher R, Verola O, Dalle S, Maubec E, Aubin F, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 2010;16:3288-95.
23. Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 2012;18:110-22
24. Fields RC, Hameed M, Qin LX, Moraco N, Jia X, Maki RG, et al. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol 2011;18:328-36.
25. Cai H, Wang Y, Wu J, Shi Y. Dermatofibrosarcoma protuberans: clinical diagnoses and treatment results of 260 cases in China. J Surg Oncol 2012;105:142-8.
26. Reimann JD, Fletcher CD. Myxoid dermatofibrosarcoma protuberans: A rare variant analyzed in a series of 23 cases. Am J Surg Pathol 2007;31:1371-7.
27. Patel KU, Szabo SS, Hernandez VS, Prieto VG, Abruzzo LV, Lazar AJ, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008;39:184-93.
28. Sciot R, Debiec-Rychter M. GIST under imatinib therapy. Semin Diagn Pathol 2006;23:84-90